losartan has been researched along with Bleeding in 15 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors aimed to test the hypothesis that xenon anesthesia limits adverse hypotensive effects of losartan during acute hemorrhage." | 7.76 | Xenon/remifentanil anesthesia protects against adverse effects of losartan on hemodynamic challenges induced by anesthesia and acute blood loss. ( Boemke, W; Francis, RC; Klein, A; Philippi-Höhne, C; Pickerodt, PA; Reyle-Hahn, MS, 2010) |
| "after a baseline awake period, anesthesia was induced in the dogs with propofol and maintained with xenon/remifentanil (baseline anesthesia)." | 7.74 | ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist. ( Boemke, W; Francis, RC; Höhne, C; Kaisers, U; Klein, A; Pickerodt, P, 2008) |
| "Our objective was to assess the effects of chronic central angiotensin II (Ang II) blockade on the basal regulation of blood pressure, heart rate (HR), arginine vasopressin (AVP), renin, epinephrine (EPI), norepinephrine (NE) and on cardiovascular and hormonal responses to hemorrhage in conscious rats." | 7.69 | Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats. ( Ahn, DK; Kim, HJ; Lee, WJ; Park, JS; Park, YY; Yang, EK, 1996) |
| "After a hemorrhage of 750 ml as a basic physiological stimulus 72 healthy male volunteers received in a parallel design either placebo (physiologic electrolyte solution) for 6 h, angiotensin II i." | 5.09 | Angiotensin II increases erythropoietin production in healthy human volunteers. ( Freudenthaler, SM; Gleiter, CH; Körner, T; Schreeb, K, 1999) |
| "The authors aimed to test the hypothesis that xenon anesthesia limits adverse hypotensive effects of losartan during acute hemorrhage." | 3.76 | Xenon/remifentanil anesthesia protects against adverse effects of losartan on hemodynamic challenges induced by anesthesia and acute blood loss. ( Boemke, W; Francis, RC; Klein, A; Philippi-Höhne, C; Pickerodt, PA; Reyle-Hahn, MS, 2010) |
| "after a baseline awake period, anesthesia was induced in the dogs with propofol and maintained with xenon/remifentanil (baseline anesthesia)." | 3.74 | ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist. ( Boemke, W; Francis, RC; Höhne, C; Kaisers, U; Klein, A; Pickerodt, P, 2008) |
| "The role of brain angiotensin II (ANG II) in mediating cardiovascular, vasopressin, and renin responses to hemorrhage was assessed in conscious spontaneously hypertensive rats (SHR) and in normotensive Wistar-Kyoto (WKY) and Wistar rats." | 3.69 | Central ANG II-receptor antagonists impair cardiovascular and vasopressin response to hemorrhage in rats. ( Ahn, DK; Kim, HJ; Lee, WJ; Park, JS; Park, YY; Yang, EK, 1995) |
| "Our objective was to assess the effects of chronic central angiotensin II (Ang II) blockade on the basal regulation of blood pressure, heart rate (HR), arginine vasopressin (AVP), renin, epinephrine (EPI), norepinephrine (NE) and on cardiovascular and hormonal responses to hemorrhage in conscious rats." | 3.69 | Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats. ( Ahn, DK; Kim, HJ; Lee, WJ; Park, JS; Park, YY; Yang, EK, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Franzén, S | 1 |
| Näslund, E | 1 |
| Wang, H | 1 |
| Frithiof, R | 2 |
| Jönsson, S | 1 |
| Melville, JM | 1 |
| Becirovic-Agic, M | 1 |
| Hultström, M | 1 |
| Truse, R | 1 |
| Voß, F | 1 |
| Herminghaus, A | 1 |
| Schulz, J | 1 |
| Weber, APM | 1 |
| Mettler-Altmann, T | 1 |
| Bauer, I | 1 |
| Picker, O | 1 |
| Vollmer, C | 1 |
| Höhne, C | 2 |
| Francis, RC | 3 |
| Pickerodt, P | 1 |
| Klein, A | 2 |
| Kaisers, U | 1 |
| Boemke, W | 3 |
| Philippi-Höhne, C | 1 |
| Pickerodt, PA | 1 |
| Reyle-Hahn, MS | 1 |
| Kaczmarczyk, G | 1 |
| Eriksson, S | 1 |
| Bayard, F | 1 |
| Svensson, T | 1 |
| Rundgren, M | 1 |
| Lee, WJ | 2 |
| Yang, EK | 2 |
| Ahn, DK | 2 |
| Park, YY | 2 |
| Park, JS | 2 |
| Kim, HJ | 2 |
| Phillips, MI | 1 |
| Heininger, F | 1 |
| Toffolo, S | 1 |
| Baujard, C | 1 |
| Ponchon, P | 3 |
| Elghozi, JL | 3 |
| Freudenthaler, SM | 1 |
| Schreeb, K | 1 |
| Körner, T | 1 |
| Gleiter, CH | 1 |
| Raiden, S | 1 |
| Pereyra, Y | 1 |
| Nahmod, V | 1 |
| Alvarez, C | 1 |
| Castello, L | 1 |
| Giordano, M | 1 |
| Geffner, J | 1 |
1 trial available for losartan and Bleeding
| Article | Year |
|---|---|
Angiotensin II increases erythropoietin production in healthy human volunteers.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pres | 1999 |
14 other studies available for losartan and Bleeding
| Article | Year |
|---|---|
Prevention of hemorrhage-induced renal vasoconstriction and hypoxia by angiotensin II type 1 receptor antagonism in pigs.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Hemodynamics; Hemorrhage; | 2021 |
Losartan does not decrease renal oxygenation and norepinephrine effects in rats after resuscitated hemorrhage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Disease Models, Animal; Hemodyn | 2018 |
Local gastric RAAS inhibition improves gastric microvascular perfusion in dogs.
Topics: Angiotensins; Animals; Dogs; Female; Gastric Mucosa; Hemodynamics; Hemorrhage; Intestines; Laser-Dop | 2019 |
ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist.
Topics: Anesthesia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Blood Pres | 2008 |
Xenon/remifentanil anesthesia protects against adverse effects of losartan on hemodynamic challenges induced by anesthesia and acute blood loss.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Dogs; Female; Hemodynamics; H | 2010 |
Effect of angiotensin II and endothelin-1 receptor blockade on the haemodynamic and hormonal changes after acute blood loss and after retransfusion in conscious dogs.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Transfusion; Car | 2004 |
Intravenous hypertonic NaCl acts via cerebral sodium-sensitive and angiotensinergic mechanisms to improve cardiac function in haemorrhaged conscious sheep.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiovascular Sys | 2007 |
Central ANG II-receptor antagonists impair cardiovascular and vasopressin response to hemorrhage in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Biphenyl Compounds; | 1995 |
The role of brain angiotensin in thirst and AVP release induced by hemorrhage.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine Vasopre | 1996 |
Effects of graded hemorrhage on short-term variability of blood pressure in conscious rats.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gas Analysis; Blood Pressure; Blood Prot | 1996 |
Contribution of humoral systems to the short-term variability of blood pressure after severe hemorrhage.
Topics: Animals; Antihypertensive Agents; Arginine Vasopressin; Biphenyl Compounds; Blood Pressure; Carbon D | 1997 |
Contribution of humoral systems to the recovery of blood pressure following severe haemorrhage.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiotensin II; Animals; Anti | 1997 |
Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cell Movement; Chemotaxis, Leukocyte; Hem | 2000 |